FAQ for Patients

Have questions about PolypDx™? We have compiled a list of frequently asked questions.

 


A polyp is a growth in the intestinal lining of the digestive system, specifically in the colon and/or rectum. 85% of colorectal cancers develop from adenomatous polyps which is why polyps are referred to as pre-cancerous.


PolypDx™ is a urine test to detect adenomatous polyps, the precursor to colorectal cancer.


    Reimbursable by FSA, HSA and HRAs

    • PolypDx™ fees are eligible for reimbursement with most flexible spending account (FSA), health savings account (HSA), or through a health reimbursement arrangement (HRA). These consumer-directed accounts can cover qualified healthcare expenses. Examples of qualified health care expenses include expenses that are part of your health insurance plan, like deductibles and copays and qualified medical expenses.

    Qualified Medical Expense under Internal Revenue Code and IRS Guidelines

    • PolypDx’s diagnostic capabilities are qualified medical expenses pursuant to the Internal Revenue Code (IRC) and Internal Revenue Services (IRS) guidelines. IRC 213(d)(1)(A) states that "medical care includes amounts paid for the diagnosis, cure, mitigation, treatment, or prevention of disease, or for the purpose of affecting any structure or function of the body." IRS Publication 502 further states that: “[y]ou can include in medical expenses the cost of devices used in diagnosing and treating illness and disease.”



PolypDx™ is designed for both men and women who are at average risk for colorectal cancer: 45-85 years of age. PolypDx™ is not intended for use in high risk individuals and is not a replacement for colonoscopy. You may be a high-risk individual if you have a personal or family history of colorectal cancer or polyps. A physician consultation is needed to determine if you are eligible for PolypDx™.


PolypDx is available as a laboratory developed test (LDT) through a CLIA certified lab. You can find more information and book a physician’s consultation at getpolypdx.com.

PolypDx™ cannot be purchased over the counter.


PolypDx™ measures small molecules (metabolites) in urine samples that are associated with the presence of polyps in the colon and rectum. These metabolites are the by-products of cellular metabolism and discarded in urine. By indicating the likely presence or absence of an adenomatous polyp, PolypDx™ may help to provide more information about whether additional follow-up, such as a colonoscopy, should be considered.


Urine collection is more convenient compared to any other specimen collection. PolypDx™ predicts the likelihood of having polyps by analyzing the level of metabolomic markers in urine.


Researchers at the University of Alberta in Edmonton, Canada studied more accurate methods to screen for colorectal cancer. After performing multiple studies, including a clinical trial of 876 participants, they completed their R&D of a biomarker panel. The test was further validated in subsequent clinical trials.


PolypDx is available as a laboratory developed test (LDT) through a CLIA certified lab. You can find more information and book a physician’s consultation at getpolypdx.com.


PolypDx™ detects 78% of adenomatous polyps, the precursor to colorectal cancer, in average risk patients.


PolypDx™ is a screening test. Any positive result should be discussed with your doctor to determine the next steps, such as a colonoscopy.


PolypDx™ is currently available as a self-pay test in the United States. You can find more information about pricing and eligibility at getpolypdx.com.


There are no special dietary restrictions or bowel preparation required prior to collecting a sample for PolypDx™.